¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

Ç÷¼ÒÆÇ-Ç÷Àü¿¬±¸È¸ P-TRG(Platelet-Thrombosis Research Group) 2023 : 2023-10-28

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 

Ç÷¼ÒÆÇ-Ç÷Àü¿¬±¸È¸ P-TRG(Platelet-Thrombosis Research Group) 2023 : 2023-10-28
±³À°ÀÏÀÚ : 2023-10-28
±³À°Àå¼Ò : ¼­¿ï ÄÚ¿¢½º, 3F ÄÁÆÛ·±½º·ë(³²) E

±³À°ÁÖÁ¦ : P-TRG(Platelet-Thrombosis Research Group) 2023

ÁÖÃÖ±â°ü : ´ëÇѽÉÇ÷°üÁßÀçÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : Ç÷¼ÒÆÇ-Ç÷Àü¿¬±¸È¸

´ã´çÀÚ : Á¶¿¹¸®
¿¬¶ôó : 02-582-8222

À̸ÞÀÏ : yehc@kscvi.org

±³À°Á¾·ù : ³»°ú

Âü¼®¿¹»óÀÎ : 100¸í
Èñ¸ÁÆòÁ¡ : 6Á¡

Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 7 ½Ã°£ 22ºÐ

¼¼ºÎ¼ö°­·á : 120,000¿ø  

ºñ°í -Á¤È¸¿ø ¹«·á µî·Ï -Àü¹®ÀÇ/°³¿øÀÇ/ÀϹÝÀÇ: 60,000 -ÀüÀÓÀÇ/Àü°øÀÇ: 30,000 -°£È£»ç/ÀÇ·á±â»ç/ÀÇ´ë»ý/±ºÀÇ°ü/°øÁߺ¸°ÇÀÇ/ÀÓ»óº´¸®»ç/Àǹ«±â·Ï»ç: 20,000 -»ê¾÷ü/±âŸ: 120,000 * ÇöÀåµî·Ï¸¸ °¡´ÉÇÕ´Ï´Ù.


±¸ºÐ ¿ùÀÏ °­ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ

±³À°½Ã°£ 10¿ù 28ÀÏ 3F ÄÁÆÛ·±½º·ë(³²) E 09:00~09:10 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥) STOPDAPT-3: An Aspirin-free Antithrombotic Strategy for Percutaneous Coronary Intervention ¿øÈ£¿¬(Áß¾ÓÀÇ´ë)

±³À°½Ã°£ 10¿ù 28ÀÏ 3F ÄÁÆÛ·±½º·ë(³²) E 09:10~09:20 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥) Optimal antiPlatelet Therapy for high Bleeding and Ischemic RISK patients - OPT-BIRISK Á¶¼º¼ö(¿¬¼¼ÀÇ´ë)

±³À°½Ã°£ 10¿ù 28ÀÏ 3F ÄÁÆÛ·±½º·ë(³²) E 09:20~09:30 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥) Aspirin versus Clopidogrel for Long-Term Maintenance Monotherapy after Percutaneous Coronary Intervention: The HOST-EXAM Extended Study °­ÁöÈÆ(¼­¿ïÀÇ´ë)

±³À°½Ã°£ 10¿ù 28ÀÏ 3F ÄÁÆÛ·±½º·ë(³²) E 09:30~09:40 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥) Bivalirudin Plus a High-dose Infusion versus Heparin Monotherapy in Patients with ST-segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: A Randomised Trial Â÷Á¤ÁØ(°í·ÁÀÇ´ë)

Åä·Ð 10¿ù 28ÀÏ 3F ÄÁÆÛ·±½º·ë(³²) E 09:40~10:00 Discussion ()

ÈÞ½Ä 10¿ù 28ÀÏ 10:00~10:20 Coffee Break ()

±³À°½Ã°£ 10¿ù 28ÀÏ 3F ÄÁÆÛ·±½º·ë(³²) E 10:20~10:35 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥) Stent Optimization Strategy May Modify DAPT(Dual Antiplatelet Therapy) ÀÌ»óÇù(¿¬¼¼ÀÇ´ë)

±³À°½Ã°£ 10¿ù 28ÀÏ 3F ÄÁÆÛ·±½º·ë(³²) E 10:35~10:50 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥) Genotyping/Platelet Reactivity Guided DAPT(Dual Antiplatelet Therapy) Duration in Selected Patients ¹®À翬(Â÷ÀÇ´ë)

±³À°½Ã°£ 10¿ù 28ÀÏ 3F ÄÁÆÛ·±½º·ë(³²) E 10:50~11:05 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥) Inflammatory Activity and Platelet Reactivity and Its Potential Effect on DAPT(Dual Antiplatelet Therapy) Á¤¿µÈÆ(Áß¾ÓÀÇ´ë)

Åä·Ð 10¿ù 28ÀÏ 3F ÄÁÆÛ·±½º·ë(³²) E 11:05~11:20 Discussion ()

±³À°½Ã°£ 10¿ù 28ÀÏ 3F ÄÁÆÛ·±½º·ë(³²) E 11:20~11:30 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥) Antithrombotic Therapy after TAVR(Transcatheter Aortic Valve Replacement) °­µµÀ±(¿ï»êÀÇ´ë)

±³À°½Ã°£ 10¿ù 28ÀÏ 3F ÄÁÆÛ·±½º·ë(³²) E 11:30~11:40 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥) Antithrombotic Therapy after LAAO(Left Atrial Appendage Occlusion) ½Å½Â¿ë(°í·ÁÀÇ´ë)

±³À°½Ã°£ 10¿ù 28ÀÏ 3F ÄÁÆÛ·±½º·ë(³²) E 11:40~11:50 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥) Antithrombotic Therapy in ASD(Atrial Septal Defect)/PFO(Patent Foramen Ovale) Closure ÀÌ¿ÀÇö(¿¬¼¼ÀÇ´ë)

±³À°½Ã°£ 10¿ù 28ÀÏ 3F ÄÁÆÛ·±½º·ë(³²) E 11:50~12:00 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥) Antithrombotic Therapy after Peripheral and Aorta Intervention ±è¿øÈ£(À»ÁöÀÇ´ë)

Åä·Ð 10¿ù 28ÀÏ 3F ÄÁÆÛ·±½º·ë(³²) E 12:00~12:20 Discussion ()

±âŸ 10¿ù 28ÀÏ 3F ÄÁÆÛ·±½º·ë(³²) E 12:20~12:30 P-TRG ÃÑȸ ()

±³À°½Ã°£ 10¿ù 28ÀÏ 3F ÄÁÆÛ·±½º·ë(³²) E 12:30~12:50 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥) PTRG-DES Consortium: Experiences from the Largest Registry of VerifyNow Test (Platelet Function and Genotype‐Related Long‐Term Prognosis in Drug‐Eluting Stent–Treated Patients With Coronary Artery Disease) Á¶Á¤·¡(ÇѸ²ÀÇ´ë)

±³À°½Ã°£ 10¿ù 28ÀÏ 3F ÄÁÆÛ·±½º·ë(³²) E 12:50~13:10 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥) Cutting Edge Care of Pitavastatin with Ezetimibe Combination Therapy Á¶»óÈ£(ÇѸ²ÀÇ´ë)

Åä·Ð 10¿ù 28ÀÏ 3F ÄÁÆÛ·±½º·ë(³²) E 13:10~13:30 Discussion ()

±³À°½Ã°£ 10¿ù 28ÀÏ 3F ÄÁÆÛ·±½º·ë(³²) E 13:30~13:45 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥) Use of TEG in ASCVD(Atherosclerotic Cardiovascular Disease) ±èÇö±¹(Á¶¼±ÀÇ´ë)

±³À°½Ã°£ 10¿ù 28ÀÏ 3F ÄÁÆÛ·±½º·ë(³²) E 13:45~14:00 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥) Evidences of Dual Pathway Inhibition Using Factor X Inhibitior in CAD(Coronary Artery Disease) ¾ÈÁØÈ£(Àü³²ÀÇ´ë)

±³À°½Ã°£ 10¿ù 28ÀÏ 3F ÄÁÆÛ·±½º·ë(³²) E 14:00~14:15 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥) Factor XI Inhibitior at Present and Future Perspectives ÀÌ»ó¿±(Áß¾ÓÀÇ´ë)

Åä·Ð 10¿ù 28ÀÏ 3F ÄÁÆÛ·±½º·ë(³²) E 14:15~14:30 Discussion ()

±³À°½Ã°£ 10¿ù 28ÀÏ 3F ÄÁÆÛ·±½º·ë(³²) E 14:30~14:45 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥) Implication of CYP2C19 Genotype and HPR on Clinical Prognosis in Korean Patients ¾È¼º±Õ(¿¬¼¼¿øÁÖÀÇ´ë)

±³À°½Ã°£ 10¿ù 28ÀÏ 3F ÄÁÆÛ·±½º·ë(³²) E 14:45~15:00 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥) Sex Differences in Midterm Prognostic Implications of High Platelet Reactivity after PCI(Percutaneous Coronary Intervention) with DES(Drug-eluting Stent) ½ÅÀº¼®(¿ï»êÀÇ´ë)

±³À°½Ã°£ 10¿ù 28ÀÏ 3F ÄÁÆÛ·±½º·ë(³²) E 15:00~15:15 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥) Implication of Diabetic Status on Platelet Reactivity and Clinical Outcomes after Drug-Eluting Stent Implantation ¼­Á¤¿ø(¼­¿ïÀÇ´ë)

Åä·Ð 10¿ù 28ÀÏ 3F ÄÁÆÛ·±½º·ë(³²) E 15:15~15:30 Discussion ()

ÈÞ½Ä 10¿ù 28ÀÏ 15:30~15:50 Coffee Break ()

±³À°½Ã°£ 10¿ù 28ÀÏ 3F ÄÁÆÛ·±½º·ë(³²) E 15:50~16:02 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥) Balancing Bleeding and Thrombosis Risks in ECMO(Extracorporeal Membrane Oxygenation)-supported Acute Myocardial Infarction Patients: A Case Study ¾ÈÇü¹ü(ºÐ´ç¼­¿ï´ëÇб³º´¿ø)

±³À°½Ã°£ 10¿ù 28ÀÏ 3F ÄÁÆÛ·±½º·ë(³²) E 16:02~16:24 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥) Successful Recovery of Maligant Acute rt MCA(Middle Cerebral Artery) infarction Combined with RCA(right coronary artery) ST Segment Elevation Myocardial Infarction ÃÖ¼ºÈ¯(ÀÎÇÏ´ëÇб³º´¿ø)

±³À°½Ã°£ 10¿ù 28ÀÏ 3F ÄÁÆÛ·±½º·ë(³²) E 16:24~16:36 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥) A Case of Acute Multiple Stent Thrombosis after PCI(Percutaneous Coronary Intervention) Àå´öÇö(ºÎõ¼¼Á¾º´¿ø)

±³À°½Ã°£ 10¿ù 28ÀÏ 3F ÄÁÆÛ·±½º·ë(³²) E 16:36~16:48 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥) Relapsed NSTEMI(Non-ST Segment Elevation Myocardial Infarction) due to Acute Gastrointestinal Bleeding after NSTEMI(Non-ST Segment Elevation Myocardial Infarction) ±èµµ¿ø(Á¤ÇÑ»ù³»°úÀÇ¿ø)

±³À°½Ã°£ 10¿ù 28ÀÏ 3F ÄÁÆÛ·±½º·ë(³²) E 16:48~17:00 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥) Acute Myocardial Infarction Patient with Severe Thrombocytopenia ±èÇü¿À(»ïÀ°¼­¿ïº´¿ø)

±³À°½Ã°£ 10¿ù 28ÀÏ 3F ÄÁÆÛ·±½º·ë(³²) E 17:00~17:12 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥) Successful PCI(Percutaneous Coronary Intervention) in Hemophilia A Patient with Acute Myocardial Infarction Occurring at a Prior Documented Minimal Coronary Artery Lesion ¹Ú»ó¹Î(³ë¿øÀ»Áö´ëÇб³º´¿ø)

±âŸ 10¿ù 28ÀÏ 3F ÄÁÆÛ·±½º·ë(³²) E 17:12~17:20 Best Presentation ½Ã»ó ()

 

ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" Ç÷¼ÒÆÇ-Ç÷Àü¿¬±¸È¸ P-TRG(Platelet-Thrombosis Research Group) 2023 : 2023-10-28""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û ´ëÇÑ°¡Á¤ÀÇÇÐȸ ÀüºÏÁöȸ Ã߰迬¼ö°­Á : 2023-10-28
´ÙÀ½±Û (¿Â¶óÀÎ)2023³âµµ Ãæû³²µµÀÇ»çȸ Ãß°èÇмú´ëȸ : 2023-10-28
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
20694 ´ëÀü Á¦8ȸ ³»ºÐºñ ÃÊÀ½ÆÄ ¹× ±â´É°Ë»ç ¿¬¼ö°­Á : 2024-06-29 0 75 2024-05-11
20693 ¼­¿ï (¿Â¶óÀÎ) ´ëÇѼ¼Æ÷º´¸®ÇÐȸ Á¦32Â÷ º´¸®Àǻ縦 À§ÇÑ ¼¼Æ÷º´¸®±³À° 4Â÷ : 2024-06-29 0 40 2024-05-11
20692 ¼­¿ï Á¦24ȸ ´ëÇÑÀ¯Àü¼º´ë»çÁúȯÇÐȸ Á¤±âÇмú´ëȸ : 2024-06-28 0 48 2024-05-11
20691 °æ±â Á¤½Å°Ç°­ÀÇÇаú ÀÓ»ó¿¡¼­ À¯¿ëÇÑ Ä¡·á¹ý : 2024-06-26 0 55 2024-05-11
20690 ¼­¿ï (¿Â¶óÀÎ)2024 ÇѾç´ëÇб³º´¿ø È£Èí±â¾Ë·¹¸£±â ¿¬¼ö°­Á : 2024-06-22 0 44 2024-05-11
20689 ºÎ»ê °í½Å´ëÇб³º¹À½º´¿ø Á¦20ȸ °©»ó¼±¿¬¼öȸ : 2024-06-22 0 45 2024-05-11
20688 ¼­¿ï (¿Â¶óÀÎ) ´ëÇѼ¼Æ÷º´¸®ÇÐȸ Á¦32Â÷ º´¸®Àǻ縦 À§ÇÑ ¼¼Æ÷º´¸®±³À° 3Â÷ : 2024-06-22 0 21 2024-05-11
20687 ¼­¿ï ´ëÇѺÎÁ¤¸ÆÇÐȸ KHRS Annual Scientific Session 2024 (2ÀÏÂ÷) : 2024-06-22 0 18 2024-05-11
20686 ¼­¿ï Á¦50Â÷ ´ëÇѾÏÇÐȸ Çмú´ëȸ 2 : 2024-06-21 0 46 2024-05-11
20685 ¼­¿ï ´ëÇѺÎÁ¤¸ÆÇÐȸ KHRS Annual Scientific Session 2024 (1ÀÏÂ÷) : 2024-06-21 0 22 2024-05-11
20684 ¼­¿ï Á¦50Â÷ ´ëÇѾÏÇÐȸ Çмú´ëȸ 1 : 2024-06-20 0 18 2024-05-11
20683 ¼­¿ï ´ëÇѸ¶ÃëÅëÁõÀÇÇÐȸ (¿Â¶óÀÎ) ¼­¿ï°æÀÎÁöȸ 277Â÷ ¿ù·ÊÁý´ãȸ : 2024-06-18 0 46 2024-05-11
20682 ¼­¿ï 2024 °­µ¿±¸ÀÇ»çȸ Á¦3Â÷ ¿¬¼ö±³À°(¿°Áõ¼º ÀåÁúȯ,ºñ¸¸ ¾à¹° Ä¡·á ) : 2024-06-17 0 31 2024-05-11
20681 ¼­¿ï ´ëÇÑ´ç´¢º´ÇÐȸ Á¦29Â÷ ´ç´¢º´ ¿¬¼ö°­Á : 2024-06-16 0 33 2024-05-11
20680 ¼­¿ï (¿Â¶óÀÎ) ´ëÇѼ¼Æ÷º´¸®ÇÐȸ Á¦32Â÷ º´¸®Àǻ縦 À§ÇÑ ¼¼Æ÷º´¸®±³À° 2Â÷ : 2024-06-15 0 28 2024-05-11
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷